Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Mol Neurobiol. 2014 Aug 2;51(3):1542–1553. doi: 10.1007/s12035-014-8830-6

Fig. 3.

Fig. 3

Low-dose candesartan treatment improves functional outcome after MCAO. Assessment of neurological deficit 1, 3, 7, and 14 days after MCAO using Bederson score (a), beam walk score (b), grip strength (c), and rotarod performance (d). Values are expressed as mean ± SEM [n=6–8/group, Bederson (#P=0.015), beam walk (#P= 0.023), grip strength (#P= 0.0031), and rotarod performance (#P<0.0001)=MCAO + saline vs MCAO + cand]